Education
About Us
Working with TipRanks
Follow Us
Molecular Partners AG (MLLCF)
OTHER OTC:MLLCF
MLLCF Stock Chart & Stats
$4.05
-$0.89(-17.80%)
At close: 4:00 PM EST
$4.05
-$0.89(-17.80%)
Day’s Range― - ―
52-Week Range$3.40 - $6.20
Previous CloseN/A
Volume100.00
Average Volume (3M)52.00
Market Cap
$180.99M
Enterprise Value$3.27M
Total Cash (Recent Filing)$104.52M
Total Debt (Recent Filing)$1.53M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Mar 12, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding40,374,640
10 Day Avg. Volume0
30 Day Avg. Volume52
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.98
Price to Sales (P/S)27.80
P/FCF Ratio-2.30
Enterprise Value/Market Cap0.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.37
Enterprise Value/Ebitda-0.06
Forecast
1Y Price Target
$3.82Price Target Upside-5.80% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial Performance2024 revenue of CHF 5MM and non-GAAP loss per share of CHF 1.59 was better than expected.
Financial PositionThe company has a solid cash position and building momentum behind innovative pipeline programs with broad potential.
Pipeline DevelopmentKey programs are on track, with MP0533 dosing in cohort 9 of its Phase I AML trial ongoing and cohort 10 being planned.
Bears Say
Workforce ReductionA workforce reduction program is being implemented.
Molecular Partners AG News
MLLCF FAQ
What was Molecular Partners AG’s price range in the past 12 months?
Molecular Partners AG lowest stock price was $3.40 and its highest was $6.20 in the past 12 months.
What is Molecular Partners AG’s market cap?
Molecular Partners AG’s market cap is $180.99M.
When is Molecular Partners AG’s upcoming earnings report date?
Molecular Partners AG’s upcoming earnings report date is Mar 12, 2026 which is in 77 days.
How were Molecular Partners AG’s earnings last quarter?
Molecular Partners AG released its earnings results on Aug 25, 2025. The company reported -$0.689 earnings per share for the quarter, missing the consensus estimate of -$0.488 by -$0.2.
Is Molecular Partners AG overvalued?
According to Wall Street analysts Molecular Partners AG’s price is currently Overvalued.
Does Molecular Partners AG pay dividends?
Molecular Partners AG does not currently pay dividends.
What is Molecular Partners AG’s EPS estimate?
Molecular Partners AG’s EPS estimate is -0.39.
How many shares outstanding does Molecular Partners AG have?
Molecular Partners AG has 40,374,640 shares outstanding.
What happened to Molecular Partners AG’s price movement after its last earnings report?
Molecular Partners AG reported an EPS of -$0.689 in its last earnings report, missing expectations of -$0.488. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Molecular Partners AG?
Currently, no hedge funds are holding shares in MLLCF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Molecular Partners AG
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
MLLCF Stock 12 Month Forecast
Average Price Target
$3.82
▼(-5.80% Downside)
Technical Analysis
Idorsia Ltd
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
RELIEF THERAPEUTICS Holding
―
Xlife Sciences Ltd.
―
Ownership Overview
―
Insiders
0.03% Other Institutional Investors
99.55% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---